甲状腺相关眼病继发高眼压的发病机制及治疗进展  

Pathogenesis and treatment progress of secondary ocular hypertension in thyroid associated ophthalmopathy

作　　者：刘晨雨 邓超华 胡维琨 LIU Chenyu;DENG Chaohua;HU Weikun(Department of Ophthalmology,Tianyou Hospital Affiliated to Wuhan University of Science and Technology,Wuhan,Hubei 430064,China;Department of Ophthalmology,Tongji Hospital Affiliated to Tongji Medical College of HUST,Wuhan,Hubei 430064,China)

机构地区：[1]武汉科技大学附属天佑医院眼科,湖北武汉430064 [2]华中科技大学同济医学院附属同济医院眼科,湖北武汉430064

出　　处：《安徽医药》2025年第5期849-856,共8页Anhui Medical and Pharmaceutical Journal

基　　金：国家自然科学基金青年科学基金项目(82101125);湖北省卫生健康委科研项目(WJ2021M211)。

摘　　要：甲状腺相关眼病(TAO)是成年人最常见的眼眶病之一。目前关于TAO的发病机制并不清楚,普遍认为其是一种自身免疫性疾病,临床表现通常有眼睑后退、眼球突出、复视、暴露性角膜炎等,也通常伴随着由多种病理生理机制引起的高眼压,但目前临床医生对TAO引起的高眼压不够重视,对于继发高眼压的治疗也不够规范。现对TAO及继发高眼压的流行病学、发病机制和治疗等方面作一概述,为临床诊断和治疗TAO所致的高眼压提供指导。Thyroid-associated ophthalmopathy(TAO)is one of the most common orbital diseases in adults.At present,the pathogenesis of TAO is not clear,and it is generally believed that it is an autoimmune disease.Clinical manifestations usually include eyelid retraction,exophthalmos,diplopia,and exposure keratitis,which are also accompanied by ocular hypertension caused by various pathological and physiological mechanisms.However,currently,clinical doctors do not pay enough attention to patients'high intraocular pressure caused by TAO,and the treatment of secondary ocular hypertension is not standardized enough.This article provides an overview of the epidemiology,pathogenesis,and treatment of thyroid-associated ophthalmopathy and secondary ocular hypertension,so as to guide clinical diagnosis and treatment of high intraocular pressure caused by TAO.

关 键 词：甲状腺功能障碍性眼病 GRAVES眼病 继发性高眼压 继发性青光眼 眼内压 

分 类 号：R581.1[医药卫生—内分泌] R771[医药卫生—内科学]